Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase-Reference-Cited by-同舟云学术

Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase

Published:2014-01-07 Issue:5 Volume:57 Page:1855-1879
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Gentles Robert G.,Ding Min,Bender John A.,Bergstrom Carl P.,Grant-Young Katharine,Hewawasam Piyasena,Hudyma Thomas,Martin Scott,Nickel Andrew,Regueiro-Ren Alicia,Tu Yong,Yang Zhong,Yeung Kap-Sun,Zheng Xiaofan,Chao Sam,Sun Jung-Hui,Beno Brett R.,Camac Daniel M.¹,Chang Chong-Hwan¹,Gao Mian¹,Morin Paul E.¹,Sheriff Steven¹,Tredup Jeff¹,Wan John¹,Witmer Mark R.¹,Xie Dianlin¹,Hanumegowda Umesh,Knipe Jay,Mosure Kathy,Santone Kenneth S.,Parker Dawn D.,Zhuo Xiaoliang,Lemm Julie,Liu Mengping,Pelosi Lenore,Rigat Karen,Voss Stacey,Wang Yi,Wang Ying-Kai,Colonno Richard J.,Gao Min,Roberts Susan B.,Gao Qi,Ng Alicia,Meanwell Nicholas A,Kadow John F.

Affiliation:

1. Bristol-Myers Squibb, US Route 206 & Province Line Road, Princeton, New Jersey 08543-4000, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm4016894

Reference88 articles.

1. Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States

2. The global burden of hepatitis C

3. Molecular viral oncology of hepatocellular carcinoma